Author: Piers Townley

Announced today, this fund will make Scotland the first country in the UK to offer cancer patients guaranteed emotional, practical and financial advice.

The National Institute for Health and Care Excellence (NICE) published draft recommendations regarding the use of cannabis-based medicinal products in England on 8 August 2019 which are unfortunately disappointing.

Researchers at St. Jude Children’s Hospital uncover the origins of medulloblastoma subgroup using single cell sequencing.

With funding from The Brain Tumour Charity, researchers in Toronto, Canada are using the power of artificial intelligence (AI) to improve brain tumour diagnosis

A report published today into the use of medicinal cannabis for problems such as nausea caused by chemotherapy says patients have had their expectations raised unfairly by a change in the law last year

Celebrating You, The Brain Tumour Charity’s community awards event, returns in May 2020 and nominations are now open!

Our Policy & Public Affairs Officer, Helena Brown, reports from Scotland

Our funded research has created a tool to help clinicians predict meningioma recurrence

In February, we co-signed a joint letter with other cancer charities to the Secretary of State for Health and Social Care which outlined concerns regarding cancer research in the UK post Brexit

Earlier this month, NHS England released their ‘Interim NHS People’s Plan’ detailing what measures will be implemented in and ahead of their full workforce proposal

Thanks to the support of our community, we’re pledging more than £3.7m to UK and international teams working towards our twin goals: doubling brain tumour survival and halving the harm caused by the disease

After undergoing an interim analysis, a phase 3 clinical trial called Toca 5 that tests a gene therapy in patients with recurrent brain cancer, will continue

Side by side, stride by stride, let’s pick up the pace of progress

Deputax-M failed to meet its target overall survival during an interim analysis of a phase 3 clinical trial in glioblastoma

Nivolumab, an immunotherapy drug, has been unsuccessful in improving overall survival in a phase 3 clinical trial when tested in newly diagnosed glioblastoma with unmethylated MGMT

New research from one of our funded grants gives much needed insight into group 3 and 4 medulloblastoma

There have been a number of headlines over the last two days about a ‘new treatment’ that may save thousands of lives for brain tumour patients

A new type of drug that targets a particular protein could become the first ever treatment designed for children with diffuse midline gliomas (formerly known as DIPG)

This weekend marks a year since Tessa Jowell died from a brain tumour

Research presented recently at a conference in Milan showed that a particular type of radiation therapy could help spare children’s memory and thinking when they undergo treatment for brain tumours

A research team from Germany has used artificial intelligence to improve the assessment of treatment response in brain tumours

NHS England are currently running a questionnaire to find out more about people’s experiences of Personal Health Budgets, which could feed into and shape the future of personalised healthcare

The Charity’s corporate partnerships officer Steve Salazar, has been pounding the training miles

A recent study highlights gaps in neuro-onoclogy services provided nationally